LENVATINIB PLUS PEMBROLIZUMAB VERSUS TREATMENT OF PHYSICIAN’S CHOICE IN PARTICIPANTS WITH ADVANCED ENDOMETRIAL CANCER: 5-YEAR OUTCOMES FROM STUDY 309/KEYNOTE-775 | Publicación